Clinical trials: Toleration
Pre-eclampsia
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
To determine the efficacy and safety of sildenafil citrate in the treatment of established pre-eclampsia
- Trial name
- NCT00141310
- Testing
- Sildenafil citrate
- Where
- 10 sites in United Kingdom
- Volunteers
- 76 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Candidiasis, Oral, HIV Infections
A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS
To compare the efficacy, safety, and tolerance of fluconazole single daily capsule for 14 days versus clotrimazole troche 5 x daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS.
- Trial name
- NCT00002282
- Testing
- Clotrimazole, Fluconazole
- Where
- 17 sites in United States
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive, Lung Diseases
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
- Trial name
- A7881013 (NCT00808288)
- Testing
- PF-00610355, PF - 00610355, PF- 00610355
- Where
- 75 sites in United States, Argentina and 10 more
- Volunteers
- 405 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study
Multiple dose safety and pharmacokinetics in healthy male subjects
- Trial name
- NCT00864786
- Testing
- PF03635659
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
HEPATITIS C (HCV)
Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554
The metabolism of PF-00868554 is primarily mediated by CYP3A, and it is anticipated that hepatic impairment will modify PF-00868554 plasma concentrations.
- Trial name
- NCT00651027
- Testing
- PF-868554
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers
The purpose of this study is to investigate safety and toleration of single oral doses as well as the time course of PF-04418948 concentration in the blood following dosing by oral solution.
- Trial name
- NCT01002963
- Testing
- PF-04418948
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 1 Diabetes
Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes
A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects with Type 1 Diabetes
- Trial name
- NCT01811849
- Testing
- Insulin LISPRO
- Volunteers
- 12 people
- Sponsor
- Biodel
Healthy
Safety And Tolerability Study Of BID Titration Scheme With PF-05089771
The most notable tolerability finding from these multiple dosing studies has been the occurrence of mild to moderate rash at doses of 450 mg BID and 600 mg BID.
- Trial name
- NCT01772264
- Testing
- PF-05089771
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Hepatic Insufficiency
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
CP-945,598 is eliminated following extensive metabolism. Decrease hepatic function can affect its elimination from the body via metabolism.
- Trial name
- NCT00645021
- Testing
- CP-945,598
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Hypertension
Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
Open label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension
- Trial name
- NCT00159887
- Testing
- Sildenafil citrate
- Where
- 65 sites in United States, Australia and 20 more
- Volunteers
- 260 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obesity
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
- Trial name
- NCT00376285
- Testing
- CP-742,033, Fenofibrate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Candidiasis, Oral, HIV Infections
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with…
- Trial name
- NCT00002112
- Testing
- Nystatin, Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Impotence
Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction
To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction.
- Trial name
- NCT00141349
- Testing
- UK-369,003
- Where
- 39 sites in United States
- Volunteers
- 300 people
- Sponsor
- Pfizer
Healthy
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
The purpose of this study is to investigate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06273340 for 14 days in healthy subjects of two age groups, aged 18-55 years (Group 1) and aged…
- Trial name
- NCT01934738
- Testing
- PF-06273340
- Where
- Belgium
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain
The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.
The purpose of the study is primarily to determine the safety and toleration and pharmacokinetics of PF-05089771 following escalating multiple doses lasting for 14 days.
- Trial name
- NCT01365637
- Testing
- PF-05089771
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Elderly
A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649
The purpose of this study in healthy elderly people is to evaluate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06743649- The pharmacodynamic activity of PF-06743649 will also be…
- Trial name
- NCT02170012
- Testing
- PF-06743649
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sexual Dysfunction, Physiological
The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.
- Trial name
- NCT00482664
- Testing
- CP-866,087
- Where
- 12 sites in Australia, Denmark and 3 more
- Volunteers
- 84 people
- Sponsor
- Pfizer
Colitis, Ulcerative
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
study to investigate the safety and efficacy properties of PF-00547659 in patients with active ulcerative colitis
- Trial name
- NCT00928681
- Testing
- Single dose-group A, Multiple dose- Group B, Multiple dose-Group B
- Where
- 18 sites in Belgium, Czechia and 5 more
- Volunteers
- 80 people
- Sponsor
- Pfizer
Obesity
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.
- Trial name
- NCT00367783
- Testing
- CP-741,952
- Where
- 5 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer